| 4.78 -0.04 (-0.83%) | 09-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.79  |
1-year : | 6.34 |
| Resists | First : | 4.96 |
Second : | 5.42 |
| Pivot price | 5.07 |
|||
| Supports | First : | 4.19 |
Second : | 3.49 |
| MAs | MA(5) : | 4.9 |
MA(20) : | 5.07  |
| MA(100) : | 4.9 |
MA(250) : | 5.57 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.8 |
D(3) : | 24.4 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 10.07 | Low : | 3.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMRX ] has closed above bottom band by 5.9%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.89 - 4.92 | 4.92 - 4.95 |
| Low: | 4.63 - 4.66 | 4.66 - 4.69 |
| Close: | 4.73 - 4.79 | 4.79 - 4.83 |
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Sat, 05 Sep 2026
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Eastern Progress
Thu, 03 Sep 2026
Immuneering to Participate in Upcoming Investor Conferences - The Manila Times
Wed, 26 Aug 2026
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Wed, 26 Aug 2026
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Thu, 06 Aug 2026
H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy - StreetInsider
Wed, 08 Jul 2026
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 55.6 (%) |
| Shares Short | 14,430 (K) |
| Shares Short P.Month | 15,210 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -52.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -5.14 |
| PEG Ratio | 0 |
| Price to Book value | 1.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|